Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.

Find out more

Latest News

Pre-clinical profile of reversible BTK inhibitor RXC005 presented at ASH 2016
6 December 2016

preview image of Redx Pharma RXC005 (REDX08608) BTK Inhibitor poster

Redx Pharma Plc is pleased to announce that it has presented the pre-clinical profile of its reversible Bruton’s tyrosine kinase (BTK) inhibitor RXC005 at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, California, United States, on 5 December 2016.

Redx’s development candidate RXC005 is a novel, potent and selective, reversible BTK inhibitor with efficacy and equivalent potency against wild-type and cysteine-481 (C481) mutated BTK.

Read more

In The Media

19 September 2016
Redx tipped to triple…

Interactive Investor

11 September 2016
Redx Pharma could soar as new drugs come on stream…

Daily Mail Midas Share Tip

6 September 2016
Redx breakthrough cancer drug remains on track…

Our Subsidiary Companies

Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.

View details

Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.

View details

Delivering multiple development candidates across a range of mechanistic approaches in cancer treatment.

View details